Lupin Limited has informed the Exchange regarding a press release dated November 04, 2021, titled "Lupin s Namuscla�� (mexiletine) is recommended by NICE for treatment of symptomatic myotonia in adults with non-dystrophic myotonic disorders".
Lupin Limited has informed the Exchange regarding a press release dated November 04, 2021, titled "Lupin s Namuscla�� (mexiletine) is recommended by NICE for treatment of symptomatic myotonia in adults with non-dystrophic myotonic disorders".